NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord 2015;30:1681-7. | USF Parkinson's Disease and Movement Disorders Center

O’Brien, CF, R Jimenez, RA Hauser, SA Factor, J Burke, D Mandri, and JC Castro-Gayol. 2015. “NBI-98854, a Selective Monoamine Transport Inhibitor for the Treatment of Tardive Dyskinesia: A Randomized, Double-Blind, Placebo-Controlled Study. Mov Disord 2015;30:1681-7.”. Mov Disord.

Last updated on 10/03/2024